SALT LAKE CITY , April 15, 2019 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) announced today that it has hired Donald J. Bray as Vice President of Business Development. Mr. Bray was formerly Vice President of Technology at Morgan Advanced Materials, where he focused on leading strategic initiatives into new market areas. Mr. Bray will assume the new role at SINTX on 22 April 2019.
“Silicon nitride is among the most advanced ceramic materials”, said Dr. Sonny Bal, Chairman and CEO of SINTX Technologies, “with applications across many industries. In addition to being approved for highly-demanding medical device applications, our formulation of silicon nitride has been characterized, validated, and tested extensively through a robust R&D program, and is fully competitive with industrial formulations required, for example, by the aerospace and defense industries. With the addition of Don, SINTX is well-positioned to focus on markets outside medical devices.”
“As SINTX explores new sources of OEM revenue and new partnerships inside and outside of health care, Don’s extensive background and experience in technical ceramics and business development are particularly relevant. In addition, Don has a proven track record of securing federal, state, and local funds in support of technology development; these skills will help SINTX continue a strategic pivot toward positioning its silicon nitride and related ceramic technologies for a broad range of medical and non-medical applications,” added Dr. Bal.
“I am thrilled to be part of the SINTX team”, said Mr. Bray. “My entire career has been spent in the advanced materials industry and I look forward to continuing that work in helping SINTX grow. They have a strong technology and manufacturing suite with many potential applications.”
About SINTX Technologies
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for biomedical applications, such as spine and dental implants. The core strength of SINTX Technologies is the research and development of medical-grade silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride spinal implants in its ISO 13485 certified manufacturing facility for CTL-Amedica, the exclusive retail channel for silicon nitride spinal implants.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. A discussion of those risks and uncertainties can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 11, 2019, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
For more information on SINTX Technologies or its silicon nitride material platform, please visit
A photo accompanying the release is available http://www.globenewswire.com/NewsRoom/AttachmentNg/0527a2a4-dd28-4a76-895e-a133d0e405b6